Stock Forecast

  PhaseBio Pharmaceuticals, Inc. ( PHAS) Stock. Should you Buy or Sell?    $ 1.10

-0.01 (-1.38 %)



PhaseBio Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol PHAS
Price $1.10
Beta 2.468
Volume Avg. $326.54 thousand
Market Cap $54.84 M
52 Week Range $0.5 - $4.1


PhaseBio Pharmaceuticals, Inc. opened the day at $1.10 which is -1.38 % on yesterday's close. PhaseBio Pharmaceuticals, Inc. has a 52 week high of $4.1 and 52 week low of $0.5, which is a difference of $3.6. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $54.84 M and total net profit is $10831 which means the company is trading at 5063.61 times profit to market capitalization. Theoretically, if you were to buy PhaseBio Pharmaceuticals, Inc. for $54.84 M, it would take 15 years to get your money back. PhaseBio Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




PhaseBio Pharmaceuticals, Inc. Stock Forecast - Is PhaseBio Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreBuy
ROA ScoreStrong Sell
DE ScoreSell
PE ScoreNeutral
PB ScoreNeutral
Overall RecommendationNeutral

Growth and Value


PE Ratio 1.925
Dividend Yiel 0.000
Net Profit Margin -2.809


Valuing PhaseBio Pharmaceuticals, Inc.


Price Book Value Ratio -0.461 Price To Book Ratio -0.461
Price To Sales Ratio -5.409 Price Earnings Ratio 1.925


How liquid is PhaseBio Pharmaceuticals, Inc.


Current Ratio 0.469
Quick Ratio 0.316


Debt


Debt Ratio 6.296 Debt Equity Ratio -1.189
Long Term Debt To Capitalization -0.007 Total Debt To Capitalization -0.048



Latest news about PhaseBio Pharmaceuticals, Inc.


PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 12/08/2022

PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 16/05/2022

PhaseBio Pulls Plug On Mid-Stage Hypertension Asset

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.

Date : 21/12/2021

PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.

Date : 15/11/2021

PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Date : 10/11/2021





About PhaseBio Pharmaceuticals, Inc.


CEO : Mr. Jonathan Mow
Sector : Healthcare
Industry : Biotechnology

Website : https://phasebio.com

Exchange : NASDAQ Global Market

Description :

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.


My Newsletter

Sign Up For Updates & Newsletters